Deutsche Bank Aktiengesellschaft Upgrades Edwards Lifesciences (NYSE:EW) to "Buy"

Edwards Lifesciences (NYSE:EW - Get Free Report) was upgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note issued on Tuesday, Marketbeat Ratings reports. The firm presently has a $103.00 target price on the medical research company's stock, up from their prior target price of $86.00. Deutsche Bank Aktiengesellschaft's target price would indicate a potential upside of 19.13% from the stock's previous close.

Other research analysts have also issued research reports about the stock. Barclays lifted their price target on shares of Edwards Lifesciences from $100.00 to $101.00 and gave the company an "overweight" rating in a research note on Tuesday, May 7th. Piper Sandler lifted their price target on shares of Edwards Lifesciences from $85.00 to $88.00 and gave the company a "neutral" rating in a research note on Friday, April 26th. Stifel Nicolaus lifted their price target on shares of Edwards Lifesciences from $83.00 to $85.00 and gave the company a "hold" rating in a research note on Friday, April 26th. Royal Bank of Canada lifted their price target on shares of Edwards Lifesciences from $95.00 to $101.00 and gave the company an "outperform" rating in a research note on Monday, April 15th. Finally, Bank of America raised shares of Edwards Lifesciences from a "neutral" rating to a "buy" rating in a research note on Thursday, March 7th. One research analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $93.88.

Edwards Lifesciences Trading Up 2.1 %

Shares of EW stock traded up $1.76 on Tuesday, reaching $86.46. 2,119,569 shares of the stock were exchanged, compared to its average volume of 3,662,030. The stock has a market cap of $52.10 billion, a PE ratio of 37.21, a P/E/G ratio of 3.65 and a beta of 1.10. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences has a one year low of $60.57 and a one year high of $96.12. The stock has a 50 day moving average price of $90.06 and a 200 day moving average price of $80.21.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a net margin of 23.01% and a return on equity of 22.86%. The company had revenue of $1.60 billion during the quarter, compared to analysts' expectations of $1.58 billion. Equities research analysts forecast that Edwards Lifesciences will post 2.77 EPS for the current fiscal year.

Insider Activity

In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the transaction, the director now owns 4,486 shares of the company's stock, valued at approximately $388,801.62. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Edwards Lifesciences news, Director Michael A. Mussallem sold 29,350 shares of the company's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $86.67, for a total transaction of $2,543,764.50. Following the sale, the director now directly owns 4,486 shares of the company's stock, valued at $388,801.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Bernard J. Zovighian purchased 580 shares of the business's stock in a transaction dated Monday, May 6th. The stock was bought at an average cost of $85.74 per share, with a total value of $49,729.20. Following the completion of the acquisition, the chief executive officer now directly owns 3,268 shares of the company's stock, valued at $280,198.32. The disclosure for this purchase can be found here. Insiders sold 213,340 shares of company stock worth $18,816,952 in the last quarter. 1.29% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the company. DSM Capital Partners LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $28,000. Crewe Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 1st quarter worth approximately $28,000. Turtle Creek Wealth Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth approximately $34,000. Riverview Trust Co bought a new position in Edwards Lifesciences in the 1st quarter valued at approximately $34,000. Finally, Pingora Partners LLC bought a new position in Edwards Lifesciences in the 4th quarter valued at approximately $38,000. Hedge funds and other institutional investors own 79.46% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.